Anabolic agents for treating postmenopausal osteoporosis;Traitement de l'ostéoporose postménopausique par les agents anaboliques

Revue du Rhumatisme (Edition Francaise)

Volumn 68, Issue 10-11, 2001, Pages 944-950

  Meunier, Pierre J ^a  

^a Hop Edouard H   (France)

Author keywords

Agents anaboliques; Anabolic agents; Fluor; Fluoride; Ost oporose postm nopausique; Parathormone; Parathyroid hormone; Postemopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; FLUOROPHOSPHATE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SIMVASTATIN; STRONTIUM; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MATRIX; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR NECK; FRACTURE; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MALE; MULTICENTER STUDY; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RAT; VERTEBRA FRACTURE;

EID: 0035724871     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(01)00207-1     Document Type: Short Survey

References (43)

1. Harris S.T., Watts N.B., Jackson R.D., Genant H.K., Wasnich R.D., Ross P., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis : 3 years of blinded therapy followed by one year of open therapy. Am J M. 95:1993;557-567.
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Newitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
3. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. J Am Med Assoc. 280:1998;2077-2082.
4. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. JAMA. 282:1999;1344-1352.
5. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J M. 344:2001;333-340.
6. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 282:1999;637-645.
7. Chesnut C.H., Silverman S., Andriano K., Genant H.K., Gimona A., Harris S., et al. Prospective, randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis : the Proof Study. Am J M. 109:2000;267-276.
8. Chapuy M.C., Arlot M.E., Delmas R.D., Meunier P.J. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J. 308:1994;1081-1082.
9. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 27:2000;687-694.
10. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J M. 344:2001;1434-1441.
11. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y.S., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J M. 322:1999;802-809.
12. Meunier P.J., Sebert J.L., Reginster J.Y., Briançon D., Appelboom T., Netter P., et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis : the FAVOS study. Osteoporos Int. 8:1998;4-12.
13. Reginster J.Y., Meurmans L., Zegels B., Rovati L.C., Minne H.W., Giacovelli G., et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized controlled trial. Ann Intern M. 129:1998;1-8.
14. Ringe J.D., Kiphoven C., Coster A., Umbach R. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium : dose related effects on bone density and fracture rate. Osteoporos Int. 9:1999;171-178.
15. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of IGF-I, IGFBP-2 and IGFBP-3 in osteoporotic patients with and without spine fractures. J Bone Miner Res. 12:1997;1272-1279.
16. Bauer D.C., Rosen C., Cauley J., Cummings S.R. Low serum IGF-I but not IGFBP-3 predicts hip and spine fracture : the study of osteoporotic fracture. abstract J Bone Miner Res. 23:(Suppl):1998;561-561.
17. Rosen C.J., Pollak M.F. IGF-I and aging : a new perspective for a new century. Trends Endocrinol Metab. 10:1999;136-142.
18. Rosen C.J., Bilezikian J.P. Anabolic therapy for osteoporosis. Clinical review 123. J Clin Endocrinol Metab. 86:2001;957-964.
19. Reeve J., Meunier P.J., Parsons J.A., Bernat M., Bijvoet O.L.M., Courpron P., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis. A multicentre trial. Br Med J. 28:1980;1340-1344.
20. Podbesek R., Edouard C., Meunier P.J., Parsons J.A., Reeve J., Stevenson R.W., et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology. 112:1983;1000-1006.
21. Hock J.M., Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 7:1992;65-72.
22. Tam C.H., Heersche J.N., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action : differential effects of intermittent and continuous administration. Endocrinology. 110:1982;506-512.
23. Kronenberg H.M. PTH : mechanism of action. Favus M. Primer on metabolic bone diseases. 3rd :1996;68-70 Lippincott Raven, Philadelphia.
24. Hock J.M., Gera I., Fonesca J., Raisz L.G., Human. PTH increases rat bone mass in ovariectomized and orchidectomized rats. Endocrinology. 122:1998;2899-2904.
25. Jilka R.I., Wernstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.G. Increased bone formation by prevention of osteoblast apoptosis with PTH. J Clin Invest. 104:1999;439-446.
26. Watson P.H., Lazowski D.A., Han V., Fraher L.J., Steer B.M., Hodsman A.B. PTH restores bone mass and enhances osteoblast IGF-I gene expression in ovariectomized rats. Bone. 16:1995;1-9.
27. Baumann B.D., Wronski T.J. Response of cortical bone to antiresorptive agents and PTH in aged ovariectomized rats. Bone. 16:1995;247-253.
28. Cheng P.T., Chan C., Muller K. Cyclical treatment of osteopenic ovariectomized adult rats with PTH (1-34) and pamidronate. J Bone Miner Res. 10:1995;119-126.
29. Slovik D.M., Rosenthal D.I., Doppelt S., Potts J.T., Daly M.A., Campbell J.R., et al. Restoration of spine bone mass in osteoporotic men by treatment with hPTH and 1,25 vitamin D. J Bone Miner Res. 1:1986;377-381.
30. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., Bilezikian J.P. Therapy of idiopathic osteoporosis in men with parathyroid hormone : effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 85:2000;3069-3076.
31. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.K., et al. Enhancement of bone mass in osteoporotic women with PTH followed by alendronate. J Clin Endocrinol Metab. 85:2000;2129-2134.
32. Lindsay R., Nieves J., Formica C., Henneman E., Woolfert L., Shen V., et al. Randomized controlled study of the effect of PTH on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 350:1997;550-555.
33. Roe E.B., Sanchez S.D., Del Puerto G.A., Pierini E., Bacchetti P., Cann C.E., et al. Parathyroid hormone 1-34 and estrogen produce dramatic bone density increases in postmenopausal osteoporosis. Results from a placebo-controlled randomized trial. abstract J Bone Miner Res. 14:(Suppl 1):1999;137-137.
34. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H.L. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate. Bone. 6:1995;603-610.
35. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1627-1633.
36. Edwards C.J., Hart D.J., Spector T.D. Statins and increased bone mineral density in postmenopausal women. Lancet. 355:2000;2218-2219.
37. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 283:2000;3205-3210.
38. Chan K.A., Andrade S.E., Boles M., Buist D.S.M., Donahue M.J., Goodman M.J., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188.
39. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 283:2000;3211-3216.
40. Van Staa T.P., Wegman S., De Vries F., Leufkens B., Cooper C. Use of statins and risk of fractures. JAMA. 285:2001;1850-1855.
41. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int. 12:2001;380-384.
42. Canalis E., Hott M., Deloffre P., Tsouderos Y., Marie P.J. The divalent salt 12 911 enhances bone replication and bone formation in vitro. Bone. 18:1996;517-523.
43. Meunier P.J., Slosman D., Delmas P.D., Sebert J.L., Albanese C., Brandi M.L., et al. Strontium ranelate as a treatment of vertebral osteoporosis. abstract J Bone Miner Res. 12:1997;107-107.